Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.45 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.45 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.45 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CSNK1A1L | Q8N752 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6448446 | 0.87 | MAPK14 (0.64) | PTGS2MAPK14ALOX5ALDH1A1CSNK1A1 | |
| SCHEMBL5500317 | 0.86 | SCD (0.54) | SCDPTGS2MAPK14ALOX5ALDH1A1 | |
| SCHEMBL5144240 | 0.81 | MAPK14 (0.51) | SCDMAPK14ALOX5ALDH1A1CSNK1A1 | |
| SCHEMBL6440993 | 0.81 | PTGS2 (0.52) | PTGS2MAPK14ALOX5ALDH1A1CSNK1A1 | |
| SCHEMBL8554519 | 0.80 | PTGS2 (0.47) | SCDPTGS2MAPK14ALOX5ALDH1A1 | |
| SCHEMBL5597148 | 0.78 | PTGS2 (0.50) | PTGS2MAPK14ALOX5ALDH1A1CSNK1A1 | |
| SCHEMBL7084420 | 0.77 | PTGS2 (0.52) | SCDPTGS2PTGS1 | |
| SCHEMBL5597026 | 0.77 | PTGS2 (0.53) | PTGS2MAPK14ALOX5ALDH1A1CSNK1A1 | |
| SCHEMBL5501473 | 0.77 | PTGS2 (0.50) | SCDPTGS2MAPK14ALOX5ALDH1A1 | |
| SCHEMBL5597237 | 0.77 | PTGS2 (0.54) | SCDPTGS2MAPK14ALOX5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050085478-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a low-molecular-weight heparin for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-04-21 | — | — | US | disclosed |
| EP-0979077-A1 | METHOD OF USING CYCLOOXYGENASE-2 INHIBITORS IN THE PREVENTION OF CARDIOVASCULAR DISORDERS | G.D. Searle & Co. (US) | 2000-02-16 | — | — | EP | disclosed |
| WO-1998047509-A1 | METHOD OF USING CYCLOOXYGENASE-2 INHIBITORS IN THE PREVENTION OF CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. (US) | 1998-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085478-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a low-molecular-weight heparin for the treatment of central nervous system damage | PTGS2, PTGS1, PTGER2 | SCD 2376/4885PTGS2 1/4885MAPK14 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.